FATE THERAPEUTICS INC (FATE): restructuring charge — Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable

FATE THERAPEUTICS INC

2025-Q2 EPS reported -$0.61 vs consensus -$0.35 ▼ miss (-74.6%)

Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.
Board approved 12% workforce reduction; expects severance charges of $0.9M–$1.2M in Q3 2025; cash runway extended through YE 2027.
FT819 SLE/LN: First patient on fludarabine-free conditioning achieved DORIS at 12-month follow-up; first extrarenal SLE patient without conditioning achieved LLDAS at 3 & 6 months.
FDA allowed IND for FT836 MICA/B-targeted CAR T-cell program; Phase 1 to test without conditioning chemotherapy in solid tumors.
Ono collaboration extended for second solid tumor CAR T candidate through at least June 2026.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

FATE THERAPEUTICS INC announced a restructuring with charges of approximately $0.9 million to $1.2 million (approximately 12%).

Type: restructuring
Charge: approximately $0.9 million to $1.2 million
Headcount: approximately 12%

Exact text from the filing

On August 7, 2025, the Company’s Board of Directors approved a corporate restructuring to streamline operations, reduce operating expenses, and extend cash runway (the “Restructuring”). In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”). Affected employees were informed on August 12, 2025. The Company expects the RIF to be completed during the third quarter of 2025, and estimates that it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs during the third quarter of 2025.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-178947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.